Development of Neuropathic Arthropathy With Entrectinib: Case Report

TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory changes with magnetic resonance imaging revealing marr...

Descripción completa

Detalles Bibliográficos
Autores principales: Giustini, Nicholas P., Oh, Hanna, Eaton, Keith D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634017/
https://www.ncbi.nlm.nih.gov/pubmed/36340796
http://dx.doi.org/10.1016/j.jtocrr.2022.100419
_version_ 1784824373653274624
author Giustini, Nicholas P.
Oh, Hanna
Eaton, Keith D.
author_facet Giustini, Nicholas P.
Oh, Hanna
Eaton, Keith D.
author_sort Giustini, Nicholas P.
collection PubMed
description TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory changes with magnetic resonance imaging revealing marrow edema. Providers should have a low threshold to investigate foot pain or gait abnormalities thoroughly with magnetic resonance imaging and referral to specialists to aid in the diagnosis of neuropathic arthropathy, with consideration to transition to an alternative agent.
format Online
Article
Text
id pubmed-9634017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96340172022-11-05 Development of Neuropathic Arthropathy With Entrectinib: Case Report Giustini, Nicholas P. Oh, Hanna Eaton, Keith D. JTO Clin Res Rep Case Report TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory changes with magnetic resonance imaging revealing marrow edema. Providers should have a low threshold to investigate foot pain or gait abnormalities thoroughly with magnetic resonance imaging and referral to specialists to aid in the diagnosis of neuropathic arthropathy, with consideration to transition to an alternative agent. Elsevier 2022-09-30 /pmc/articles/PMC9634017/ /pubmed/36340796 http://dx.doi.org/10.1016/j.jtocrr.2022.100419 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Giustini, Nicholas P.
Oh, Hanna
Eaton, Keith D.
Development of Neuropathic Arthropathy With Entrectinib: Case Report
title Development of Neuropathic Arthropathy With Entrectinib: Case Report
title_full Development of Neuropathic Arthropathy With Entrectinib: Case Report
title_fullStr Development of Neuropathic Arthropathy With Entrectinib: Case Report
title_full_unstemmed Development of Neuropathic Arthropathy With Entrectinib: Case Report
title_short Development of Neuropathic Arthropathy With Entrectinib: Case Report
title_sort development of neuropathic arthropathy with entrectinib: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634017/
https://www.ncbi.nlm.nih.gov/pubmed/36340796
http://dx.doi.org/10.1016/j.jtocrr.2022.100419
work_keys_str_mv AT giustininicholasp developmentofneuropathicarthropathywithentrectinibcasereport
AT ohhanna developmentofneuropathicarthropathywithentrectinibcasereport
AT eatonkeithd developmentofneuropathicarthropathywithentrectinibcasereport

Ejemplares similares